Metraipolis › archive › dc_b954aeda58c0
Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights — Europe PMC PMID:42148068
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42148068
- DOI
- 10.3389/fimmu.2026.1727925
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T22:08:04.488Z
- SHA-256 of the archived text
fcc980cf3353d16b776da0c5e3bfaaae31ab9b6d6f16bd90f0c5c7f861e3841e- Stable URL of this page
https://metraipolis.com/documento/dc_b954aeda58c0
How to cite
Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights — Europe PMC PMID:42148068 — Europe PMC (en), https://europepmc.org/article/MED/42148068 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b954aeda58c0 (Metraipolis archive dc_b954aeda58c0, sha256 fcc980cf3353d16b776da0c5e3bfaaae31ab9b6d6f16bd90f0c5c7f861e3841e)
BibTeX
@misc{dcb954aeda58c0,
title = {Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights — Europe PMC PMID:42148068},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42148068},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b954aeda58c0; sha256 fcc980cf3353d16b776da0c5e3bfaaae31ab9b6d6f16bd90f0c5c7f861e3841e},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42148068. Agents can read the archived copy with the MCP tool read_document.